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Abstract
The potential inhibitory effect of diverse triazolyl-ferrocene steroids on key enzymes of the estrogen biosynthesis was 
investigated. Test compounds were synthesized via copper-catalyzed cycloaddition of steroidal azides and ferrocenyl-
alkynes using our efficient methodology published previously. Inhibition of human aromatase, steroid sulfatase (STS) and 
17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) activities was investigated with in vitro radiosubstrate incubations. 
Some of the test compounds were found to be potent inhibitors of the STS. A compound bearing ferrocenyl side chain on 
the C-2 displayed a reversible inhibition, whereas C-16 and C-17 derivatives displayed competitive irreversible binding 
mechanism toward the enzyme. 17α-Triazolyl-ferrocene derivatives of 17β-estradiol exerted outstanding inhibitory effect 
and experiments demonstrated a key role of the ferrocenyl moiety in the enhanced binding affinity. Submicromolar  IC50 
and Ki parameters enroll these compounds to the group of the most effective STS inhibitors published so far. STS inhibitory 
potential of the steroidal ferrocenes may lead to the development of novel compounds able to suppress in situ biosynthesis 
of 17β-estradiol in target tissues.
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Introduction
The ferrocene substituent features exceptional biomedical 
properties. Ferrocene-cinchona hybrids containing a tria-
zole linker were shown to exert antiproliferative effect on 
HepG2 hepatoma and HT-29 colorectal adenocarcinoma 
human tumor cell lines [20]. Triazole-linked isatin-ferro-
cene conjugates exhibited selectivity against the hormone-
dependent (MCF-7) cell line [42]. Steroid-ferrocene hybrids 
are believed to have a vast potential for medical application 
[2, 23, 27, 46]. Steroidal ferrocenes were aimed mainly to 
be applied for vectorization of the DNA damaging effect of 
the ferrocene entity to produce cytotoxic effect in cancer-
ous cells [18]. C-2, C-16 and C-17 ferrocene derivatives 
of androgens as well as C-3, C-7, C-16 and C-17 ferrocene 
derivatives of 17β-estradiol and estrone demonstrated con-
siderable antiproliferative effects (micromolar  IC50 or  GI50 
values) against hormone-independent cancerous cell lines 
[18, 23, 49, 51, 53]. Concurrently, hormonal effects exerted 
on the specific sexual steroid receptors were also investi-
gated. Low affinities to the androgen receptor were detected 
for the ferrocene derivatives of androgens [2, 53]. The C-7 
and C-17 ferrocene derivatives of 17β-estradiol displayed 
estrogen receptor-binding and estrogenic effect comparable 
to those of 17β-estradiol [31, 52], whereas the C-3 deriva-
tive has a predicted estrogen receptor antagonistic effect 
[51]. Potential inhibitory effect of the ferrocene steroid 
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compounds exerted on enzymes of the steroid metabolism 
has not yet been investigated, to the best of our knowledge.
Estrogens are biosynthesized from their steroidal pre-
cursors via aromatization of their ring A (Fig. 1). The 
process is catalyzed by the cytochrom P450-dependent 
aromatase (EC 1.14.14.1). This enzyme converts mainly 
androst-4-ene-3,17-dione and a minor amount of tes-
tosterone into estrone and 17β-estradiol, respectively. 
The estrogen reservoir estrone-3-sulfate is formed from 
estrone, which can be then regenerated with a hydrolysis 
catalyzed by steroid sulfatase (STS, EC 3.1.6.2). Estrone is 
converted to the active hormone 17β-estradiol by the stere-
ospecific reduction in the C-17 oxo function. This reaction 
is accomplished by 17β-hydroxysteroid dehydrogenases 
type 1 (17β-HSD1, EC 1.1.1.62), an enzyme belonging 
to the short-chain alcohol dehydrogenase superfamily 
[19]. Estrogens have a major role in the development and 
progression of gynecological pathologies, with hormone-
dependent forms of breast cancer among them. Breast 
cancer tissues have been shown to express enzymes of the 
estrogen producing machinery in an exaggerated manner 
[1]. The increased expression resulted in elevated local 
17β-estradiol concentration, which is believed to promote 
the pathophysiological cell proliferation. Estrogen abla-
tion achieved by blocked biosynthesis can be successfully 
applied in the pharmacotherapy of the hormone-depend-
ent tumors; therefore, aromatase, STS and 17β-HSD1 are 
interesting topics of anticancer drug development [19, 47]. 
The three-dimensional crystal structures of human aro-
matase, STS and 17β-HSD1 have been explored, and bind-
ing cavities and key amino acid residues involved in the 
binding have been identified [14, 15, 17]. These investiga-
tions provided valuable information on the molecular basis 
of substrate-binding and catalytic mechanisms; however, 
they proved to be less useful in the inhibitor design [19]. 
Majority of the inhibitors of enzymes of the estrogen bio-
synthesis have been developed by ligand-based approach. 
Experimental testing and biochemical analysis of inhibi-
tion of novel compounds are, therefore, still a feasible way 
of inhibitor development.
In this study, we aimed to investigate the inhibitory 
effects of diverse triazolyl-ferrocene steroids exerted on 
the activity of key enzymes of the estrogen biosynthesis. 
The triazoles were obtained by copper-catalyzed azide-
alkyne cycloaddition using steroidal azides and ferrocene-
substituted alkynes or ferrocenyl azides and alkynyl ster-
oids as substrates. We investigated one newly synthesized 
ferrocenyl steroid as well as other derivatives that were 
prepared previously, and the details were reported in for-
mer publications [11, 44, 45]. A related phenyl-triazolyl 
compound (Fehér et al. [12] and cited literature therein) 
and two non-ferrocenyl steroid precursors [44] were also 
included in the present experiments for the investigation 
of structure–activity aspects.
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Fig. 1  Key enzymes of the estrogen biosynthesis. Aromatase (EC 
1.14.14.1). 17β-HSD1: 17β-hydroxysteroid dehydrogenases type 
1 (EC 1.1.1.62). STS: steroid sulfatase (EC 3.1.6.2). 17β-HSD3: 
17β-hydroxysteroid dehydrogenases type 3 (EC 1.1.1.64), not inves-
tigated. 17β-HSD5: 17β-hydroxysteroid dehydrogenases type 5 
(EC 1.1.1.239), not investigated
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Materials and methods
Test substances
The test substances were re-synthesized according to the 
procedures described previously.
1—2β-(4-Ferrocenyl-1,2,3-triazol-1-yl)-3α-hydroxy-
5α-androstane-17-one [11].
2—2β-(4- ( (E ) -E thyl  3 - fe r rocenylacr yla te -2-
methylcarbamoyl))-1,2,3-triazol-1-yl)-3α-hydroxy-5α-
androstan-17-one [11].
3—6β-(4- ( (E ) -E thyl  3 - fe r rocenylacr yla te -2-
methylcarbamoyl)-1,2,3-triazol-1-yl)-3α,5α-dihydroxy-
androstan-17-one [11].
4—16β-(4-Ferrocenyl-1,2,3-triazol-1-yl)-17α-hydroxy-
5α-androstane [11].
5—16β-(4-((E) -Ethyl  3-fer rocenylacrylate-2-
methylcarbamoyl)-1,2,3-triazol-1-yl)-17α-hydroxy-5α-
androstane [11].
6—17-(N-(1-(1-ferrocenyl-ethyl)-1,2,3-triazol-4-yl)-
methyl-carbamoyl)-4-aza-5α-androst-16-en-3-one, 1/1 
mixture of two epimers [44].
7—17-(N-(prop-2-ynyl)-carbamoyl)-4-aza-5α-androst-
16-en-3-one [44].
8—17-(N-(1-(1-ferrocenyl-ethyl)-1,2,3-triazol-4-yl)-
methyl-carbamoyl)-3-methoxy-estra-1,3,5(10),16-tetraene, 
1/1 mixture of two epimers [44].
9—17-(N-(prop-2-ynyl)-carbamoyl)-3-methoxy-estra-
1,3,5(10),16-tetraene [44].
10—17α-(1-Ferrocenylmethyl-1H-1,2,3-triazol-4-yl)
estradiol [12].
11—17α-(1-(1-Ferrocenyl-ethyl)-1,2,3-triazol-4-yl)-
3,17β-dihydroxy-estra-1,3,5(10)-triene, 1/1 mixture of 
two epimers [45].
12—17α-(1-Ferrocenylmethyl-1H-1,2,3-triazol-4-yl)-
17β-hydroxy-18a-homo-19-nor-androst-4-ene-3-one.
Compound 12 was synthesized via reaction of levonorg-
estrel and azidomethylferrocene and was purified by col-
umn chromatography. Synthesis method in detail and char-
acterization data are described in Supplementary Material.
13—17α-(1-Benzyl-1H-1,2,3-triazol-4-yl)estradiol 
[12].
Enzyme experiments
Activity and inhibition of the aromatase, 17β-HSD1 and 
STS enzymes were assessed with radioincubation methods 
described in detail in our previous publications [3, 16]. 
These methods are based on adapted literature techniques 
and used human placental microsoma suspension and cyto-
sol as source of the enzymes (references: for aromatase 
[48]; for 17β-HSD1 [50]; and for STS [21]. Incubation 
parameters were optimized in preliminary experiments. 
Enzyme reactions applied for the measurement of inhibi-
tory effect satisfied conditions of the initial velocity meas-
urements. Conversion rate in the non-inhibited control 
incubates was between 10 and 13%, and product forma-
tion was proportional to the enzyme concentration and 
the incubation time. Here, we provide short descriptions 
of methods applied in the enzyme experiments. (Chemi-
cals and materials as well as the preparation of cytosol 
and microsomal fractions are described in Supplementary 
Material.)
Incubation procedures and measurement of inhibitory 
effect
Enzymatic incubations were carried out in 0.1 M HEPES 
buffer medium at a final volume of 200 µl. The substrate 
was added to incubate in 20 µl of 25 v/v % propylene glycol 
in HEPES buffer solution, whereas test compounds were 
applied in 10 µl of dimethyl sulfoxide solution. Incubations 
were performed at 37 °C and terminated by cooling and by 
the addition of organic solvents of the subsequent extraction 
procedure. The radioactivity of the isolated enzyme prod-
ucts was measured by means of liquid scintillation counting. 
Control samples with no inhibitor and blank samples were 
incubated simultaneously.
In incubates of the inhibition studies, substrate concen-
tration was 1.0 µM, and test compounds were applied at 
10 µM. Relative conversions compared to non-inhibited con-
trols (100%) were determined. The assays were performed 
in triplicate, and the mean value and the standard deviation 
(SD) were calculated.
IC50 values (the inhibitor concentration that decreases the 
enzyme activity to 50%) were determined for the most effec-
tive test compounds and for certain reference compounds. In 
these cases, conversions were measured at 10–15 different 
concentrations in the appropriate interval between 0.001 and 
50 µM.  IC50 results were calculated by using unweighted 
iterative least squares logistic curve fitting by means of the 
“absolute  IC50 calculation” function of the GraphPad Prism 
4.0 software (GraphPad Software, Inc., San Diego, CA, 
USA).
Aromatase assay
In the aromatase inhibition assays, the human placental 
microsoma suspension (5 µl) was incubated with testoster-
one substrate spiked with [1,2,6,7-3H]testosterone tracer, in 
the presence of 0.1 mM NADPH cofactor excess. Incuba-
tion time was 40 min. The incubation mixture was extracted 
with 700 µl toluene, and the toluene phase was drained and 
washed with equal volume of HEPES buffer. Aromatase 
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products containing phenolic hydroxy group were extracted 
with 1.2 M sodium hydroxide solution from the toluene 
extract.
17β‑HSD1 assay
In the 17β-HSD1 inhibition assays, cytosol fraction of 
human placenta (50 µl of 25-fold diluted) was incubated 
using estrone substrate containing [6,7-3H]estrone tracer, 
in the presence of 0.1 mM NADPH cofactor excess. The 
incubation time was 2.5 min. The product 17β-estradiol was 
extracted with 100 µl ethyl acetate and isolated by a TLC 
method performed on silica gel plate and with dichlorometh-
ane/diisopropyl ether/ethyl acetate (75:15:10 v/v) eluent.
STS assay
STS assays were performed using human placental micro-
somas (10 µl of 100-fold diluted) and estrone-3-sulfate 
substrate with [6,7-3H]estrone-3-sulfate tracer. Incubations 
lasted for 20 min. Reactions were terminated by the addition 
of equal volume of methanol, and the product 17β-estradiol 
was extracted with 400 µl toluene.
Reversibility studies and kinetic analyses of STS inhibitors
In the reversibility studies, inhibitor compounds were pre-
incubated with the human microsomal placenta fraction in 
a volume of 4.0 µl at 37 °C for 2.5 or 20 min. Following this 
procedure, samples were diluted with the incubation medium 
Table 1  Inhibition and kinetic 
parameters of the enzyme 
activities determined for 
the substrate and reference 
compounds
IC50: concentration which decreases the enzyme activity to 50%
KM: The Michaelis constant (KM) of substrates was measured using increasing concentration of the unla-
beled substrate
Ki: Inhibitor constant determined from Dixon’s plot
SD: standard deviation
Compound Structure Inhibition and kinetic parameters of enzyme activities
IC50 ± SD (µM) or Ki ± SD (µM) or KM ± SD (µM)
Aromatase STS 17β-HSD1
Testosterone
 O
OH
H H
H
IC50 = 0.52 ± 0.14
Estrone-3-sulfate  
O
O
H H
H
SHO
O
O
 
IC50 = 5.2 ± 1.2
KM = 8.5 ± 2.9
Estrone  
HO
O
H H
H
 
IC50 = 0.63 ± 0.11
17β-Estradiol  
HO
OH
H H
H
 
IC50 = 9.0 ± 4.0
EMATE  
O
O
H H
H
SH2N
O
O
 
IC50 = 0.0098 ± 0.0038
Ki = 0.0044 ± 0.0005
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Table 2  In vitro inhibition of enzyme activities by the test compounds
No. Structure Inhibition of enzyme activities
Relative conversion ± SD
Aromatase STS 17β-HSD1
1
H
H H
H
O
N
HO
NN
Fe
100 ± 11 41 ± 5 81 ± 8
2
H
H H
H
O
N
HO
NNNH
O
EtO2C H
Fe
78 ± 7 90 ± 9 93 ± 2
3
H
H H
OH
O
HO
N
N
N
HN
O
EtO2C
H
Fe
101 ± 10 97 ± 10 89 ± 4
4
H
H H
H
OH
N
NN
Fe
93 ± 6 85 ± 6 94 ± 7
5
H
H H
H
OH
N
NN
NHO
EtO2C H
Fe
89 ± 2 42 ± 3 91 ± 10
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Table 2  (continued)
No. Structure Inhibition of enzyme activities
Relative conversion ± SD
Aromatase STS 17β-HSD1
6
N
H
H
H H
O H
N
H
O
N
N
N
Fe
82 ± 7 87 ± 4 65 ± 13
7
N
H
H
H H
O H
N
H
O
83 ± 4 93 ± 6 101 ± 8
8
H
H H
O H
N
O
N
N
N
Fe
82 ± 5 68 ± 5 85 ± 5
9
H
H H
O H
N
O
94 ± 3 75 ± 8 91 ± 6
10
Fe
H
H H
OH
N
N
N
HO
89 ± 8 8.2 ± 1.8 98 ± 10
11
Fe
H
H H
OH
N
N
N
HO
117 ± 15 1.0 ± 0.5 76 ± 6
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to 50-fold. Enzyme activity measurements were taken after 
20 min secondary incubation time to allow dissociation. The 
enzymatic reactions were started by the addition of the sub-
strate (1.0 µM final concentration of estrone-3-sulfate with 
tracer), and subsequent incubation procedures were then car-
ried out as described. Conversions were compared to their 
respective controls, which were treated in a similar way, but 
without inhibitors.
Kinetic analyses were performed via measurement of 
the enzymatic transformation using different fixed substrate 
concentrations (1–5 µM) and varied inhibitor concentrations 
(0–0.17 µM). The KM parameter of the STS was calculated 
from Michaelis–Menten analysis (non-inhibited reaction 
velocity vs. substrate concentration) using the GraphPad 
Prism 4.0 software. The Dixon’s linear transformation (1/
velocity vs. inhibitor concentration) was applied for evalu-
ation, and the inhibition constant (Ki) was determined from 
abscissa of intersection of the lines of different substrate 
concentrations. Mechanism of binding was identified accord-
ing to the Dixon’s graphs and the secondary plot of slopes of 
the Dixon’s lines vs. 1/substrate concentration.
Results
Enzyme inhibition experiments of the steroidal ferro-
cenes were performed by in vitro radiosubstrate incuba-
tions using human term placental microsoma suspension 
and cytosol as enzyme sources ([3, 16] and corresponding 
references therein). Aromatase inhibition was tested by 
the transformation of testosterone to 17β-estradiol, and 
STS inhibition was investigated via hydrolytic release of 
estrone from estrone-3-sulfate, whereas the influence on 
17β-HSD1 was measured on estrone to 17β-estradiol con-
version. Relative conversions compared to non-inhibited 
controls (100%) were measured in the presence of 10 μM 
concentration of the test compounds; for more efficient 
compounds,  IC50 values were determined. Inhibitory 
potentials and binding affinities of the test compounds 
were assessed also in comparison with  IC50 data of the 
corresponding substrate.  IC50 parameters of 17β-estradiol 
and estrone-3-sulfamate (EMATE) as references were 
also determined in our STS assay. (Results are listed in 
Table 1.) Mechanistic and kinetic investigations were per-
formed, and inhibitory constants (Ki) were determined for 
selected compounds.
Table 2  (continued)
No. Structure Inhibition of enzyme activities
Relative conversion ± SD
Aromatase STS 17β-HSD1
12
H H
H H
O
OH
N
N
N Fe
93 ± 5 77 ± 7 89 ± 9
13
H
H H
OH
N
N
N
HO
90 ± 5 17 ± 5 100 ± 7
Relative conversions measured in the presence of 10 μM concentration of the compound tested. (Control incubation with no inhibition is 100%.) 
Mean ± SD, n = 3
SD: standard deviation
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Aromatase inhibition results of the test compounds
In our experiments, substances 2, 6 and 8 in the applied 
10 μM test concentration suppress aromatase activity to 
around 80% of the relative conversions (Table 2). These 
results mean  IC50 values exceeding 10  μM and indi-
cate very weak inhibitory potentials. Other investigated 
compounds have even weaker effects, resulting in relative 
conversions close to 90% or higher.
17β‑HSD1 inhibition results of the test compounds
Our test substances 6 and 11 inhibited 17β-HSD1 activ-
ity to relative conversions 65% and 76%, respectively 
Table 3  In vitro STS inhibition results of the most potent test compounds
IC50: the inhibitor concentration which decreases the enzyme activity to 50%
Ki: Inhibitor constant determined from Dixon’s plot
SD: standard deviation
No. Structure Inhibition of STS
IC50 ± SD (µM) Ki ± SD (µM)
1
H
H H
H
O
N
HO
NN
Fe
4.63 ± 1.51
5
H
H H
H
OH
N
NN
NHO
EtO2C H
Fe
2.39 ± 1.10
10
Fe
H
H H
OH
N
N
N
HO
0.0844 ± 0.0427 0.0661 ± 0.0086
11
Fe
H
H H
OH
N
N
N
HO
0.0350 ± 0.0058 0.0212 ± 0.0045
13
H
H H
OH
N
N
N
HO
1.02 ± 0.601
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(Table 2). These results show weak inhibitions even in 
the relatively high 10 μM test concentration. Other test 
compounds displayed even weaker effects, since relative 
conversions were not decreased below 80% in the experi-
ments where they were applied.
STS inhibition results of the test compounds
In our experiments, the 3α-hydroxy-5α-androstane-17-one 
compound derivatized with triazolyl-ferrocene in position 
2β (1) exerts potent inhibition, and the  IC50 result 4.6 μM 
(Tables 2 and 3) reveals a binding affinity similar to that 
of the substrate estrone-3-sulfate  (IC50 result 5.2  μM). 
The insertion of an ethylacrylate group in the side chain 
of the compound 2 diminishes the inhibitory effect almost 
completely. Another 3α-hydroxy-5α-androstane-17-one 
derivative bearing a similar elongated ferrocenyl side chain 
in position 6β and additionally a 5α-hydroxy group (3) is 
found to be also ineffective against STS. The 17α-hydroxy-
5α-androstane compound with 16β-triazolyl-ferrocene (4) 
has a weak effect, but its counterpart 5 bearing the ethyl-
acrylate elongated triazolyl-ferrocene side chain is a potent 
inhibitor.  IC50 value of this compound (2.4 μM) indicates a 
twofold affinity compared to the substrate estrone-3-sulfate. 
Substances 6 and 8 display relative conversion results 87% 
and 68%, respectively. These values indicate that either 
isomers of the substituted 4-aza-3-oxo-androstene and the 
3-methoxy-estratetraene compounds are very weak inhibi-
tors. These triazolyl-ferrocene-derivatized substances, nev-
ertheless, exert somewhat more potent inhibition than their 
carbamoyl-propene precursor compounds 7 and 9 (relative 
conversions are 93% and 75%, respectively).
The 17α-triazolyl-ferrocene derivative of 17β-estradiol 
(10) exerts highly potent inhibition.  IC50 value of this 
compound is 0.084 μM, indicating a more than 60-fold 
stronger binding compared to the substrate estrone-
3-sulfate (Table 2 and Fig. 2). Substance 11 (consists of 
the methyl-substituted isomer counterparts) displays an 
even more potent inhibition, and its apparent  IC50 value 
of 0.035 μM is close to that of the reference EMATE 
(0.0098 μM). A related ferrocenyl compound 12 which 
possesses 4-ene-3-oxo structure in its ring A and an ethyl 
group on the C-13 has a very weak effect with a rela-
tive conversion result of 77%. The analogue compound 13 
bearing phenyl group attached to the triazole ring has also 
potent inhibitory effect showing an  IC50 result of 1.0 μM.
Potent test substances (1, 5, 10 and 11) and the refer-
ence competitive irreversible inhibitor EMATE were sub-
jected to mechanistic and kinetic investigations. In revers-
ibility tests performed with 1, the preincubated and diluted 
samples resulted in higher conversions (Fig. 3, conditions 
C and D), similar to the results measured for lower concen-
tration of the test compound (Fig. 3, conditions A). This 
means that 1 can be released from binding by dilution and 
this inhibitor binds to the enzyme in a reversible manner. 
In case of 5, 10 and 11, results of the preincubated and 
diluted samples (Fig. 3, conditions C and D) were similar 
to that obtained for incubations with higher concentration 
of the inhibitor (Fig. 3, conditions B). This means that 
these inhibitors are not released from binding upon dilu-
tion and they are bound to the enzyme irreversibly during 
the preincubation period. Time course experiments reveal 
that the binding processes are completed within 2.5 min, 
in a relatively short period when compared to the time of 
incubation.
Kinetic investigations were performed with test sub-
stances 10, 11 and reference EMATE. The Dixon’s plot pro-
vided straight lines at different fixed substrate concentrations 
intersecting in the second quadrant characterizing the com-
petitive inhibition mechanism (Fig. 4, part A). The replots of 
slopes vs. 1/substrate concentration resulted in a straight line 
through the origin (insets in part B of Fig. 4) which confirms 
the competitive binding manner [10, 40] that means that 
these inhibitors occupy the substrate-binding place of the 
EMATE   10 11
[I] (µM)
Rel. conv. %
0.0001 0.001 0.01 0.1 1 10 100
20
40
60
80
100
[I] (µM)
Rel. conv. %
0.01 0.1 1 10 100
20
40
60
80
100
[I] (µM)
Rel. conv. %
0.01 0.1 1 10 100
20
40
60
80
100
IC50= 0.0098 μM IC50= 0.084 μM IC50= 0.035 μM
Fig. 2  Concentration-dependent STS inhibition of reference EMATE 
and compounds 10 and 11. Inhibited relative conversion results (Rel. 
conv.) vs. inhibitor concentration.  IC50 value, the inhibitor concentra-
tion which decreases the enzyme activity to 50%, was calculated by 
using unweighted iterative least squares logistic curve fitting
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enzyme. Ki parameters were found to be 0.066 μM for 10, 
0.021 μM for 11 and 0.0044 μM for the reference EMATE 
(Fig. 4 part A). Inhibitory potentials on the basis of these Ki 
data were comparable to those obtained by the  IC50 values. 
Determined Ki values are substantially lower than the KM 
parameter of estrone-3-sulfate (8.5 μM) that reflects the sig-
nificantly higher binding affinities of these inhibitors when 
compared to the substrate.
Discussion
Inhibition of aromatase
Structural studies of aromatase have revealed that the struc-
ture of substrate-binding site provides specificity toward 
androgens [14]. Numerous derivatives of the preferred 
substrate androst-4-ene-3,17-dione have been found potent 
inhibitors, and the 4-hydroxy- and the 6-methylidene-
1,4-diene analogues of the androst-4-ene-3,17-dione (form-
estane and exemestane, respectively) have been applied in 
the medical practice [55]. Structure–activity investigations 
have found that planarity of the ring A (4-ene or 1,4-diene 
structure), preferred anellation of the ring A and ring B 
junction (5α-epimers) and the presence of either apolar or 
polar substituents on the C-4, C-6 and C-7 carbons enhance 
the binding affinity of the inhibitors [7]. It has been also 
revealed that androst-4-ene-3,17-dione derivatives were able 
to bind the enzyme in the absence of 3-oxo function. Potent 
inhibitory effect of 16β-imidazolyl androst-4-ene-3,17-dione 
derivatives has been reported, too [4]. Aromatase inhibi-
tors were also found among product-like compounds, and 
2-chloro- and 6α-phenyl-estrones were the most powerful 
members of the series investigated [3, 28]. It is worth men-
tioning that conjugated aromatic systems containing triazole 
cycle are common structural elements of nonsteroidal aro-
matase inhibitors [5, 38]. Corresponding further literature 
references can be found in the comprehensive review articles 
on aromatase inhibitors published by Baston and Leroux [5], 
Santen et al. [38] and Yadav et al. [55].
Various structural elements of referred aromatase inhib-
itor examples can be recognized in our test compounds. 
Certain test compounds bear substrate-like 4-en-3-oxo 
structure or possess ring A with similar planarity to the 
4-aza-3-oxo moiety, whereas others possess product-like 
estrane core. Some investigated compounds have side 
chain in position C-2, C-6 and C-16, and the ferrocenyl 
substituents bear a triazolyl group. Similarities to known 
aromatase inhibitors made our compounds reasonable tar-
gets for aromatase inhibition tests. Experiments, however, 
revealed that none of the test compounds exerted substan-
tial inhibitory effect against the human aromatase activity.
Inhibition of 17β‑HSD1
The substrate-binding site of 17β-HSD1 has been identified 
as a hydrophobic tunnel with polar residues at each end [17, 
39]. Further extensive inhibitor research works demonstrated 
that the binding cavity is complementary to the C18 steroi-
dal scaffold of the main natural substrate estrone. 17β-HSD1 
is multispecific in terms of binding other, non-cognate ste-
roidal substrates, e.g., C19 androstenes or androstanes, 
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Fig. 3  Investigation of reversibility of STS inhibition. Effect of 
the potent test substances 1, 5, 10 and 11 and the reference com-
petitive irreversible inhibitor EMATE were assessed by dilution 
method. Placental microsomes were preincubated in samples of A 
and B in the absence of inhibitors, whereas preincubations were 
performed in samples of C and D with high inhibitor concentrations 
(2–5xIC50). Following preincubation, samples were diluted 50-fold. 
Samples A were then supplemented with high concentration of 
inhibitors (2–5xIC50), whereas 50-fold lower concentrations of the 
inhibitors (0.04–0.1xIC50) were added to the samples B. Inhibited 
activities of STS were subsequently measured by the usual radioin-
cubation method. Samples C and D are different in time of preincu-
bation (2.5  min and 20  min, respectively). Each column represents 
mean ± SD of three separate experiments. Compound 1 acts by a 
reversible process, as the STS activities in the samples C and D cor-
respond to results obtained for the sample A containing low inhibitor 
concentration. STS activities in the samples C and D of 5, 10 and 11 
and EMATE correspond to results obtained for the sample B contain-
ing high inhibitor concentration; therefore, these compounds behave 
as irreversible inhibitors. Experimental conditions (other details 
are given in Enzyme experiments part of the Materials and meth-
ods): A Preincubation in the absence of inhibitor. STS measurement 
with lower inhibitor conc.: EMATE 0.001 μM; 1, 5 0.2 μM; 10, 11 
0.01 μM. B Preincubation in the absence of inhibitor. STS measure-
ment with higher inhibitor conc.: EMATE 0.05 μM; 1, 5 10 μM; 10, 
11 0.5 μM. C Preincubation for 2.5 min with higher inhibitor conc. 
EMATE 0.05  μM; 1, 5 10  μM; 10, 11 0.5  μM, STS measurement 
with lower inhibitor conc.: EMATE 0.001 μM; 1, 5 0.2 μM; 10, 11 
0.01  μM. D Preincubation for 20  min, with higher inhibitor conc. 
EMATE 0.05  μM; 1, 5 10  μM; 10, 11 0.5  μM, STS measurement 
with lower inhibitor conc.: EMATE 0.001 μM; 1, 5 0.2 μM; 10, 11 
0.01 μM
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even in alternative binding orientations. Adjacent cavities 
and subpockets can be found around the substrate-binding 
site which is able to accommodate various side chains on 
the steroidal C-2 position or on the ring D (positions C-15, 
C-16 and C-17). These interactions improve binding affinity 
and enhance inhibitory potential considerably. Estrone and 
17β-estradiol derivatives possessing aromatic substituents 
on C-2 or C-16 [33] and also those bearing triazolyl-aryl 
side chain on C-15 [24] or on a D-seco structure [43] were 
found to be efficient 17β-HSD1 inhibitors. Readers may find 
reference details of these literature data in our previous pub-
lications [3, 43] and in review articles on 17β-HSD1 inhibi-
tors from Brožič et al. [6] and Poirier [33].
17β-HSD1 is able to bind compounds containing various 
steroidal cores, and suitable substituents among them aro-
matic side chains in position C-2, C-15, C-16 and C-17, may 
enhance the binding affinity of these compounds. Several 
structural features of our steroidal ferrocenes resemble to 
known 17β-HSD1 inhibitors; nevertheless, our tested com-
pounds did not exert considerable inhibition on the 17β-
HSD1 activity under our experimental conditions.
Inhibition of STS
Protein of the STS consists of a globular polar domain and a 
hydrophobic transmembrane stem domain, resembling to a 
mushroom in that overall tertiary shape of the enzyme. The 
substrate-binding site situated in a cavity lies at the base 
of the globular domain, just at the top of the stem domain 
[17]. STS hydrolyzes various physiological substrates 
to their unconjugated forms, including 3-sulfate ester of 
estrone, dehydroepiandrosterone, pregnenolone and cho-
lesterol. Numerous other compounds proved to be capable 
of binding to the enzyme and demonstrated effective inhibi-
tion toward the sulfatase activity [22, 30, 41, 54]. A large 
group of these inhibitors are ester derivatives which apply 
the FGly75 inactivation mechanism by their acid residue. 
Most of these, either steroidal or nonsteroidal compounds, 
are sulfamates, and the first and still the best known example 
of these irreversible inhibitors is EMATE [36].
Various estrane-, androstane- and pregnane-based com-
pounds exert inhibitory effect toward the STS, and their 
binding affinity to the enzyme can be largely modified by 
substituents on the steroid skeleton [22, 30, 41, 54]. Certain 
halogens or other small electron withdrawing groups (cyano 
and nitro) in position 2 and/or 4 of the steroidal ring A may 
enhance the inhibitory potential [3, 25, 29, 32]. Reason of 
the enhanced binding is not known; nevertheless, the exist-
ence of cavities able to accommodate these substituents 
could be postulated. Amino acids which might be involved 
in putative electrostatic or hydrogen-binding interactions 
in the proximity of position 2 (Lys134, Lys368, His136, 
His290 and His346) and position 4 (Lys368, Lys134 and 
Arg79) are also proposed [25, 32, 36].
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Fig. 4  Dixon’s kinetic analysis reference EMATE and compounds 10 
and 11. Row A: Dixon’s plots provided straight lines at different fixed 
substrate concentrations. Lines intersecting in the second quadrant 
characterize the competitive inhibition mechanism. Row B: Second-
ary plot of slopes of the Dixon’s lines vs. 1/substrate concentration. 
Straight lines through the origin characterize the competitive binding 
manner (corresponding references: [10, 40])
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Literature results have also revealed that appropriate side 
chains on the ring D might also improve binding affinity 
of the steroidal inhibitors [41]. 17α-Benzyl or alkyl deriva-
tives of 17β-estradiol display enhanced inhibitor potential 
[13, 34]. Hydrophobic substituents on the aromatic cycle 
might further improve the inhibitory effect [8], and relatively 
rigid 17α-moieties (cyclic substituent attached with only one 
rotatable bond, a methylene group) were more advantageous 
in the binding. 16α-Benzyl- and 16β-benzyl-substituted 
compounds exert also augmented inhibition compared to 
their parent compound 17β-estradiol, although they are 
much less potent than their 17α counterparts. These find-
ings indicated non-specific hydrophobic interactions of the 
D-ring side chains with hydrophobic residues in a long, deep 
and narrow pocket in the D-ring area [13]. Non-competitive 
or mixed type reversible inhibition of the 17α-benzyl-17β-
estradiol suggested the existence of two proximate-binding 
sites involved in the binding of this inhibitor [8, 25]. One of 
them allows the steroidal part to bind, whereas another one, 
an allosteric-binding site, establishes non-specific hydro-
phobic interactions of the D-ring side chains. The latter is 
formed by hydrophobic residues in a long and narrow pocket 
located between the two hydrophobic α-helices and buried in 
the transmembrane domain [13, 26]. Authors Fournier and 
Poirier postulated that inhibitory potency might be increased 
by maximizing interactions with both the substrate and the 
allosteric-binding sites [13]. Considering enhanced inhibitor 
potency of further steroidal compounds bearing C-17 aryl 
group, a π–π-type interaction to the Phe residues present at 
the entrance of α-helices of the binding site have also been 
hypothesized [9, 41]. Large affinity difference which was 
observed between 17β-arylsulfonamide and 17β-arylamide 
derivatives of estra-1,3,5(10)-trien-3-ol indicated that other 
non-hydrophobic interactions of the linker which attach the 
aryl function might also play a key role in potent inhibition 
[25, 26].
STS inhibition data of the investigated steroidal ferro-
cene compounds reveal that the 17α-triazolyl-ferrocene 
derivative of 17β-estradiol (10) is a highly potent inhibitor 
of this enzyme. The submicromolar  IC50 and Ki parame-
ters enroll this compound to the group of the most effec-
tive steroidal STS inhibitors known to date [22, 30, 41, 
54]. Inhibitory potential of this compound is similar to 
that of the optimized 17α-benzyl-17β-estradiol derivatives 
 (IC50 = 0.022–0.310 μM) reported by the Poirier’s group, 
among which a bicyclic 4-benzyloxybenzyl derivative was 
the most effective inhibitor [30, 34]. Our test compound 10 
also bears a bicyclic aromatic 17α substituent and both of 
its triazolyl and ferrocenyl moieties bear a pronounced phar-
macophore character.
In order to investigate structural features contributing to 
the outstanding inhibitory potential of compound 10, we may 
compare this finding with the results of the triazolyl-benzene 
derivative 13 and their parent compound 17β-estradiol. Both 
17α-substituted compounds have markedly enhanced effect 
when compared to 17β-estradiol  (IC50 = 9.0 μM), and the 
presence of ferrocenyl moiety instead of phenyl group results 
in a further 12-fold increase in the inhibition. Ferrocene and 
phenyl ring has been used to replace each other mutually 
and can be regarded as bioisosteric functional groups in 
drug compounds. Concerning inhibition toward STS, the 
ferrocenyl analogue exerts a considerably higher potential, 
indicating a crucial and specific function of this moiety in 
the binding of the inhibitor to this enzyme.
Substance 11 contains methylated derivatives of 10. 
Although substance 11 is a mixture of epimers, it displays 
regular behavior in inhibition experiments (Figs. 2 and 
4). Measured apparent  IC50 and Ki parameters can reli-
ably reflect the inhibitory effect, and these values indicate 
further enhanced potential when compared to that of the 
non-methylated counterpart. Structural aspects cannot 
be identified precisely; nevertheless, results of substance 
11 emphasize that further optimization of the binding of 
17α-triazolyl-ferrocene derivatives is possible even with 
minor modification(s) of the linker part between the triazolyl 
and ferrocenyl structures of the side chain.
In kinetic experiments, 10 displayed a competitive behav-
ior. It is most likely that substrate-binding cavity is occupied 
by the 17β-estradiol part of the molecule. Ring A accommo-
dated in the active center of the enzyme, and the ring D with 
the 17α-triazolyl-ferrocene side chain is directed toward the 
transmembrane domain of the STS. Literature references 
indicate that C-17 aryl substituents may interact with Phe 
and other hydrophobic amino acids of the α-helices in this 
domain (Fournier and Poirier 1998; [9, 41]. We may also 
postulate that the 17α-triazolyl-ferrocene side chain of 10 
can have access to these residues, and the enhanced binding 
affinity of this compound can be explained by similar mecha-
nisms, namely by π–π-type interactions toward Phe residues 
present at the entrance of α-helices as well as by non-specific 
hydrophobic interactions directed to suitable residues buried 
deeper in the tunnel of the α-helices. Competitive inhibition 
pattern also suggests that the 17α-triazolyl-ferrocene side 
chain is long and flexible enough to allow 17β-estradiol part 
to bind into the substrate-binding cavity, which means that 
these types of derivatives may be able to maximize interac-
tions with both binding sites.
16β-Triazolyl-ferrocene-17α-hydroxy-5α-androstane (4) 
has a weak inhibitory effect, whereas 5 which bears an ethy-
lacrylate triazolyl-ferrocene substituent on C-16 proved to 
be a potent inhibitor. It seems that an elongated ferrocenyl 
side chain is preferred for the binding of C-16-substituted 
derivatives. Ferrocenyl moiety attached to a longer and flex-
ible linker may reach the binding pocket which otherwise is 
situated closer and positioned more appropriately for C-17 
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substituents [34], and this might be the reason for a better 
binding affinity of 5 to the STS.
In the case of the tested two 2β-substituted 3α-hydroxy-
5α-androstane-17-one compounds, the shorter triazolyl-
ferrocene substituent of 1 proved to be advantageous con-
cerning the affinity to the STS. It may be postulated that 
this triazolyl-ferrocene side chain is capable of interacting 
with residues of the binding cavity supposed to exist in the 
proximity of the ligands’ position 2 [25, 36].
Examples of the potent test compounds (1, 5 and 10) 
show that various steroidal backbones may provide suitable 
core for ferrocenyl derivative STS inhibitors. Comparison 
of the highly potent 17α-triazolyl-ferrocene derivative of 
17β-estradiol (10) and its 4-ene-3-oxo analogue (12), a weak 
inhibitor, reveals that in other cases the steroidal scaffold has 
a strong influence on the STS inhibitory potential.
Mechanistic experiments indicate a reversible binding 
mode for the C-2-substituted triazolyl-ferrocene derivative 
1 and an irreversible binding mechanism for the C-16 and 
C-17 derivatives 5, 10 and substance 11. This binding dif-
ference approves that different interactions may be involved 
in the binding of the C-2 triazolyl-ferrocene derivative and 
the compounds substituted on their ring D. Our inhibitors 
do not possess arylsulfamate moiety, which is usually the 
active principle of the irreversible STS inhibitors; neither 
bear other reactive group capable of forming covalent bind-
ing to certain enzyme residues. Steroidal ferrocenes and 
the enzyme, therefore, are likely to establish non-covalent 
adducts, but the interactions can be so tight in certain cases 
that the inhibitors will be bound essentially irreversibly.
Biomedical relevance
In cancerous breast tissues, 17β-estradiol can be formed 
in situ from estrone, which is generated also locally either 
via the aromatase route (aromatization of adrenal androst-
4-ene-3,17-dione) or the sulfatase route (desulfation of 
estrone-3-sulfate). It is considered that sulfatase path-
way predominates, and around tenfold greater amount of 
estrone may be produced via the sulfatase route rather than 
via the aromatase pathway [19, 29]. Inhibition of STS is, 
therefore, a particularly attractive manner of antiestrogenic 
pharmacotherapy of the estrogen-dependent breast cancer 
[35, 37]. Numerous STS inhibitors were developed in the 
last decades, but none of them have been introduced into 
the medical practice till now [35]; Rizner [37, 47]. There 
still remains a considerable demand for a new class of STS 
inhibitor compounds. Our results on STS inhibitory potential 
of certain ferrocenyl steroids seem therefore to be particu-
larly promising.
When an irreversible inhibitor is used as medicinal agent, 
effect can be maintained after its clearance from the sys-
tem, and a de novo biosynthesis of the enzyme protein is 
required for the restoration of the original enzyme activity. 
Advantages of the resulting prolonged pharmacodynamics 
include lower level and frequency of dosing as well as sup-
pressed extent of side effects. EMATE-based irreversible 
inhibitors, however, have the drawback that the STS inacti-
vation process releases steroidal compounds bearing estro-
genic hormonal effect [36]. Binding of steroidal ferrocenes 
does not transform the inhibitor molecule, and the irrevers-
ible inhibition without generating hormonally active agents 
makes steroidal ferrocenes superior to EMATE derivatives 
in a presumed pharmacological application.
Various steroidal ferrocene compounds bear cytotoxic 
effects which evolve hormone-independent antiprolifera-
tive effects in cancerous cells [18, 23, 49, 51, 53]. Recently 
tested derivatives and their analogues may also bear such 
a cytotoxic potential. A hypothesized synergism between 
the hormone-independent cytotoxicity and the suppressed 
estrogen-dependent cell proliferation evolved by the inhib-
ited STS activity might be particularly advantageous in the 
treatment of breast cancer.
Conclusion for future biology
We investigated in vitro inhibitory effects of ten diverse 
steroidal ferrocene substances exerted on key enzymes of 
the estrogen biosynthesis. Numerous structural elements 
of these derivatives resemble to those of known potent 
aromatase and 17β-HSD1 inhibitors; nevertheless, our 
test compounds were found weakly effective against these 
enzymes. We observed a potent inhibition against STS by 
three triazolyl-ferrocene derivatives which display stronger 
affinities to the enzyme than the substrate estrone-3-sulfate 
itself. Compound with triazolyl-ferrocene substituent on C-2 
is bound in a reversible manner, whereas the C-16 and C-17 
derivatives are irreversible inhibitors. Related non-ferroce-
nyl compounds are found to exert lower potency, indicating 
that the ferrocene moiety may have a specific function in the 
enhanced affinity to the STS. Based on literature references, 
interactions of the 16β- and 17α-triazolyl-ferrocenes with 
Phe residues and with other hydrophobic amino acids of the 
transmembrane helices can be proposed. Comparison of ade-
quate counterparts revealed a profound influence of the ste-
roidal backbone and of the linker part in the ferrocenyl side 
chains on the STS inhibition. Our most potent STS inhibi-
tor, the 17α-triazolyl-ferrocene derivative of 17β-estradiol 
(10) presents submicromolar  IC50 and Ki parameters, and 
therefore, this compound belongs to the group of the most 
effective STS inhibitors published so far. Our results indicate 
that optimized combination of structural elements (steroidal 
core, ferrocenyl side chain, position of the substitution) may 
further enhance STS inhibitory potential of the steroidal fer-
rocenes. STS inhibitory potential of the steroidal ferrocenes 
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may lead to the development of novel compounds able to 
suppress in situ 17β-estradiol production in target tissues. 
A presumed synergism between the hormone-independent 
cytotoxicity and the suppressed estrogen-dependent cell 
proliferation can make this type of compounds particularly 
promising drug candidates for the pharmacological therapy 
of hormone-dependent breast cancer.
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